These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 31585024)

  • 41. Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin.
    Linde L; Boelz S; Nissim-Rafinia M; Oren YS; Wilschanski M; Yaacov Y; Virgilis D; Neu-Yilik G; Kulozik AE; Kerem E; Kerem B
    J Clin Invest; 2007 Mar; 117(3):683-92. PubMed ID: 17290305
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CFTR mRNAs with nonsense codons are degraded by the SMG6-mediated endonucleolytic decay pathway.
    Sanderlin EJ; Keenan MM; Mense M; Revenko AS; Monia BP; Guo S; Huang L
    Nat Commun; 2022 Apr; 13(1):2344. PubMed ID: 35487895
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeting Nonsense: Optimization of 1,2,4-Oxadiazole TRIDs to Rescue CFTR Expression and Functionality in Cystic Fibrosis Cell Model Systems.
    Pibiri I; Melfi R; Tutone M; Di Leonardo A; Pace A; Lentini L
    Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32899265
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nanomolar-potency 'co-potentiator' therapy for cystic fibrosis caused by a defined subset of minimal function CFTR mutants.
    Phuan PW; Tan JA; Rivera AA; Zlock L; Nielson DW; Finkbeiner WE; Haggie PM; Verkman AS
    Sci Rep; 2019 Nov; 9(1):17640. PubMed ID: 31776420
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Enhancement of premature stop codon readthrough in the CFTR gene by Ataluren (PTC124) derivatives.
    Pibiri I; Lentini L; Melfi R; Gallucci G; Pace A; Spinello A; Barone G; Di Leonardo A
    Eur J Med Chem; 2015 Aug; 101():236-44. PubMed ID: 26142488
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Correctors and Potentiators Rescue Function of the Truncated W1282X-Cystic Fibrosis Transmembrane Regulator (CFTR) Translation Product.
    Haggie PM; Phuan PW; Tan JA; Xu H; Avramescu RG; Perdomo D; Zlock L; Nielson DW; Finkbeiner WE; Lukacs GL; Verkman AS
    J Biol Chem; 2017 Jan; 292(3):771-785. PubMed ID: 27895116
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Generation of an induced pluripotent stem cell line (IGGi002A) from nasal cells of a cystic fibrosis patient homozygous for the G542X-CFTR mutation.
    Dębczyński M; Mojsak D; Tamburro S; Baldassari S; Musante I; Casciaro R; Ciciriello F; Zara F; Scudieri P; Gorrieri G
    Stem Cell Res; 2023 Oct; 72():103232. PubMed ID: 37865062
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Isogenic cell models of cystic fibrosis-causing variants in natively expressing pulmonary epithelial cells.
    Valley HC; Bukis KM; Bell A; Cheng Y; Wong E; Jordan NJ; Allaire NE; Sivachenko A; Liang F; Bihler H; Thomas PJ; Mahiou J; Mense M
    J Cyst Fibros; 2019 Jul; 18(4):476-483. PubMed ID: 30563749
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The suppression of premature termination codons and the repair of splicing mutations in CFTR.
    Oren YS; Pranke IM; Kerem B; Sermet-Gaudelus I
    Curr Opin Pharmacol; 2017 Jun; 34():125-131. PubMed ID: 29128743
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nonsense-mediated mRNA decay and cystic fibrosis.
    Linde L; Kerem B
    Methods Mol Biol; 2011; 741():137-54. PubMed ID: 21594783
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Physiological and pharmacological characterization of the N1303K mutant CFTR.
    DeStefano S; Gees M; Hwang TC
    J Cyst Fibros; 2018 Sep; 17(5):573-581. PubMed ID: 29887518
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Two Small Molecules Restore Stability to a Subpopulation of the Cystic Fibrosis Transmembrane Conductance Regulator with the Predominant Disease-causing Mutation.
    Meng X; Wang Y; Wang X; Wrennall JA; Rimington TL; Li H; Cai Z; Ford RC; Sheppard DN
    J Biol Chem; 2017 Mar; 292(9):3706-3719. PubMed ID: 28087700
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ataluren in cystic fibrosis: development, clinical studies and where are we now?
    Zainal Abidin N; Haq IJ; Gardner AI; Brodlie M
    Expert Opin Pharmacother; 2017 Sep; 18(13):1363-1371. PubMed ID: 28730885
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Investigating the Inhibition of FTSJ1, a Tryptophan tRNA-Specific 2'-O-Methyltransferase by NV TRIDs, as a Mechanism of Readthrough in Nonsense Mutated CFTR.
    Carollo PS; Tutone M; Culletta G; Fiduccia I; Corrao F; Pibiri I; Di Leonardo A; Zizzo MG; Melfi R; Pace A; Almerico AM; Lentini L
    Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298560
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
    Pettit RS
    Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antisense oligonucleotide splicing modulation as a novel Cystic Fibrosis therapeutic approach for the W1282X nonsense mutation.
    Oren YS; Avizur-Barchad O; Ozeri-Galai E; Elgrabli R; Schirelman MR; Blinder T; Stampfer CD; Ordan M; Laselva O; Cohen-Cymberknoh M; Kerem E; Bear CE; Kerem B
    J Cyst Fibros; 2022 Jul; 21(4):630-636. PubMed ID: 34972649
    [TBL] [Abstract][Full Text] [Related]  

  • 57. No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations.
    Clancy JP; Rowe SM; Bebok Z; Aitken ML; Gibson R; Zeitlin P; Berclaz P; Moss R; Knowles MR; Oster RA; Mayer-Hamblett N; Ramsey B
    Am J Respir Cell Mol Biol; 2007 Jul; 37(1):57-66. PubMed ID: 17347447
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rescuing the CFTR protein function: Introducing 1,3,4-oxadiazoles as translational readthrough inducing drugs.
    Pibiri I; Lentini L; Melfi R; Tutone M; Baldassano S; Ricco Galluzzo P; Di Leonardo A; Pace A
    Eur J Med Chem; 2018 Nov; 159():126-142. PubMed ID: 30278331
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical doses of amikacin provide more effective suppression of the human CFTR-G542X stop mutation than gentamicin in a transgenic CF mouse model.
    Du M; Keeling KM; Fan L; Liu X; Kovaçs T; Sorscher E; Bedwell DM
    J Mol Med (Berl); 2006 Jul; 84(7):573-82. PubMed ID: 16541275
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Converting nonhydrolyzable nucleotides to strong cystic fibrosis transmembrane conductance regulator (CFTR) agonists by gain of function (GOF) mutations.
    Okeyo G; Wang W; Wei S; Kirk KL
    J Biol Chem; 2013 Jun; 288(24):17122-33. PubMed ID: 23620589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.